Abstract
The past decades have been marked by spectacular progress towards understanding how dendritic cells (DCs) interact with T cells to elicit protective immune responses to fight infectious diseases and cancer. DCs that are lying at the interface between innate and adaptive immunity, are educated in peripheral tissues prior to their journey to the secondary lymphoid organs (SLO) whereby they dictate different classes of T cell responses. Uncontrolled or unwanted inflammatory responses are the price to pay to eliminate pathogens. However, if not self-limited, they may induce collateral damages that result in chronic inflammation often associated with autoimmune disorders. CD47 and its two ligands, i.e. thrombospondin 1 (TSP-1) and SIRP-α, were identified as a previously unappreciated inhibitory axis of DC and T cell functions. TSP-1 is predominantly a negative regulator of DC and T cell function while basal SIRP-α ligation on APC by CD47 enforces tolerance. Yet, CD47/SIRP-α interaction positively controls DC and innate cell transendothelial migration. Due to the promiscuity of the protein interactions for CD47 and its ligands, it is quite interesting to note that deletion of the CD47 gene in mice largely agrees with the in vitro data with human cells. In fact, the well-conserved tissue distribution of CD47 and SIRP-α across species may facilitate the transition from bench to bedside. We thus propose CD47/TSP- 1/SIRP-α axis as an important sensor to maintain homeostasis and regulate innate and adaptive immune responses.
Keywords: Thrombospondin, dendritic cells (DCs), T cells, immune responses, infectious diseases, secondary lymphoid organs (SLO), pathogens, chronic inflammation, CD47, LIGANDS
Current Drug Targets
Title: CD47 in the Immune Response: Role of Thrombospondin and SIRP-α Reverse Signaling
Volume: 9 Issue: 10
Author(s): Marika Sarfati, Genevieve Fortin, Marianne Raymond and Santos Susin
Affiliation:
Keywords: Thrombospondin, dendritic cells (DCs), T cells, immune responses, infectious diseases, secondary lymphoid organs (SLO), pathogens, chronic inflammation, CD47, LIGANDS
Abstract: The past decades have been marked by spectacular progress towards understanding how dendritic cells (DCs) interact with T cells to elicit protective immune responses to fight infectious diseases and cancer. DCs that are lying at the interface between innate and adaptive immunity, are educated in peripheral tissues prior to their journey to the secondary lymphoid organs (SLO) whereby they dictate different classes of T cell responses. Uncontrolled or unwanted inflammatory responses are the price to pay to eliminate pathogens. However, if not self-limited, they may induce collateral damages that result in chronic inflammation often associated with autoimmune disorders. CD47 and its two ligands, i.e. thrombospondin 1 (TSP-1) and SIRP-α, were identified as a previously unappreciated inhibitory axis of DC and T cell functions. TSP-1 is predominantly a negative regulator of DC and T cell function while basal SIRP-α ligation on APC by CD47 enforces tolerance. Yet, CD47/SIRP-α interaction positively controls DC and innate cell transendothelial migration. Due to the promiscuity of the protein interactions for CD47 and its ligands, it is quite interesting to note that deletion of the CD47 gene in mice largely agrees with the in vitro data with human cells. In fact, the well-conserved tissue distribution of CD47 and SIRP-α across species may facilitate the transition from bench to bedside. We thus propose CD47/TSP- 1/SIRP-α axis as an important sensor to maintain homeostasis and regulate innate and adaptive immune responses.
Export Options
About this article
Cite this article as:
Sarfati Marika, Fortin Genevieve, Raymond Marianne and Susin Santos, CD47 in the Immune Response: Role of Thrombospondin and SIRP-α Reverse Signaling, Current Drug Targets 2008; 9 (10) . https://dx.doi.org/10.2174/138945008785909310
DOI https://dx.doi.org/10.2174/138945008785909310 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
Current Pharmaceutical Design Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections
Current Pharmaceutical Design Antibodies As Promising Novel Neuroprotective Agents in the Central Nervous System Injuries
Central Nervous System Agents in Medicinal Chemistry Neuroinflammation and Immunity: A New Pharmacological Target in Depression
CNS & Neurological Disorders - Drug Targets Colloidal Polymeric Nanoparticles and Brain Drug Delivery
Current Drug Delivery Recent Developments of Thalidomide Derivatives Possessing Anti-Inflammatory Activity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Tuning Immune Suppression in Systemic Autoimmunity with Self-Derived Peptides
Inflammation & Allergy - Drug Targets (Discontinued) Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry Failure of Immune Homeostasis - The Consequences of Under and Over Reactivity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Differential Enhancement of T Helper Type 1 (Th1)/Th2 Cytokine Production by Natural Killer T Cells Through Negative Feedback Regulation with Cytokine-conditioned Dendritic Cells
Current Immunology Reviews (Discontinued) Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Protein Glycation: An Old Villain is Shedding Secrets
Combinatorial Chemistry & High Throughput Screening Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulatory T Cells and Tolerogenic Dendritic Cells as Critical Immune Modulators in Atherogenesis
Current Pharmaceutical Design The TOLL-like / Type-I Interferon Pathways as Emerging Therapeutic Targets for Autoimmune Diseases
Drug Design Reviews - Online (Discontinued)